We are focused on developing differentiated products that improve the prevention and treatment of infectious diseases. Our clinical-stage programs include Aurexis^®, a humanized monoclonal antibody for the adjunct treatment of serious S. aureus infections, and FV-100, a potent antiviral small molecule for the treatment of herpes zoster (shingles). Programs in pre-clinical development include compounds for HIV , HCV and cytomegalovirus.